Approval of biosimilars in indications for which they were not studied directly in phase 3 clinical trials relies on the extrapolation of indications, a concept that is scientifically justified but, nevertheless, has generated some concerns among clinicians. In the case of biosimilar infliximab CT-P13 (Inflectra, Remsima), some gastroenterologists have voiced a lack of confidence in the biosimilar for the treatment of inflammatory bowel disease, including Crohn disease (CD) and ulcerative colitis. Now, head-to-head study, published in The Lancet, has produced data that may help allay those worries.
Approval of biosimilars in indications for which they were not studied directly in phase 3 clinical trials relies on the extrapolation of indications, a concept that is scientifically justified but, nevertheless, has generated some concerns among clinicians. In the case of biosimilar infliximab CT-P13 (Inflectra, Remsima), some gastroenterologists have voiced a lack of confidence in the biosimilar for the treatment of inflammatory bowel disease, including Crohn disease (CD) and ulcerative colitis. Now, head-to-head study, published in The Lancet, has produced data that may help allay those worries.
Between 2014 and 2017, the randomized, multicenter, double-blind, phase 3 noninferiority PLANETCD study enrolled 220 patients with active CD who were naïve to biologic therapy. The patients were randomized to receive CT-P13 only (n = 56), CT-P13 followed by reference infliximab (n = 55), reference infliximab only (n = 54), or reference infliximab followed by CT-P13 (n = 55), with a switch taking place at week 30.
Patients received 5 mg/kg of their assigned infliximab treatment at weeks 0, 2, 6, followed by every 8 weeks up to week 54. The study’s primary end point was the proportion of patients with a decrease of 70 points or more in the Crohn’s Disease Activity Index (CADI-70) from baseline to week 6. The prespecified noninferiority margin was set at −20%.
The CDAI-70 response rates at week 6 were similar for the patients who began their treatment with CT-P13. Among those who either took CT-P13 only or began with CT-P13 and switched to reference infliximab, 69.4% achieved CDAI-70 (95% CI, 59.9%-77.8%). Among those who took reference infliximab only or began treatment with reference infliximab and then switched to CT-P13, 74.3% achieved CDAI-70 (95% CI, 65.1%-82.2%), for a difference of −4.9% (95% CI, −16.9% to 7.3%), which fell within the prespecified noninferiority margin.
Overall, 67% of patients of patients experienced at least 1 treatment-emergent adverse event (TEAE), with 64% of patients in the CT-P13-only group, 62% in the CT-P13 to infliximab switch group, 69% in the infliximab only group, and 73% in the infliximab to CT-P13 switch group experiencing a TEAE.
“This is the first head-to-head study demonstrating the equal efficacy of an anti-TNF [anti−tumor necrosis factor] biosimilar in inflammatory bowel disease,” said Stefan Schreiber, MD, director of the Clinic for Internal Medicine at Kiel Campus of the University Hospital Schleswig-Holstein in Germany, in a statement on the PLANETCD study. “This robust evidence makes a compelling case for the use of biosimilars and will inform decision-making by gastroenterologists when choosing anti-TNF therapy for their patients,” he added.
Hyoung-Ki Kim, vice chairman at Celltrion Healthcare, added, “The PLANETCD study is the first investigation of the therapeutic efficacy of an infliximab biosimilar powered to show noninferiority to reference infliximab in inflammatory bowel disease…[PLANETCD] together with the evidence from the influential NOR-SWITCH study, which was performed across multiple indications, support the equivalence between CT-P13 and reference infliximab.”
Reference
Ye BD, Pesegova M, Alexeeva O, Osipenko M, Lahat A, Dorofeyev A. Efficacy and safety of biosimilar CT-P13 compared with originator infliximab in patients with active Crohn’s disease: an international, randomised, double-blind, phase 3 non-inferiority study [published online, March 28, 2019]. Lancet. doi: 10.1016/S0140-6736(18)32196-2.
Biosimilars in America: Overcoming Barriers and Maximizing Impact
July 21st 2024Join us as we explore the complexities of the US biosimilars market, discussing legislative influences, payer and provider adoption factors, and strategies to overcome industry challenges with expert insights from Kyle Noonan, PharmD, MS, value & access strategy manager at Cencora.
Patient-Reported Outcomes Similar Between Adalimumab-adbm, Reference Product in VOLTAIRE-RA Study
September 28th 2024A summary of research written by Vibeke Strand, MD, clinical professor in division of immunology/rheumatology at Stanford University School of Medicine, gave an overview of patient-reported outcomes (PROs) in the VOLTAIRE-RA trial.
Biosimilars Gastroenterology Roundup for May 2024—Podcast Edition
June 2nd 2024On this episode of Not So Different, we review the biggest gastroenterology biosimilar stories from May 2024, covering new data from conferences and journals on infliximab and adalimumab products that demonstrate positive clinical results and confirm the safety of these biosimilars, as well as the feasibility of switching to them.
AAM Report: Despite Massive Savings, Patient OOP Costs on Biosimilars, Generics Remain High, Part 2
September 24th 2024Part 2 of our series diving into the Association for Accessible Medicines' (AAM) latest report discusses that while generics and biosimilars saved $445 billion in 2023, their potential is hindered by high patient costs, drug shortages, and ineffective policies, underscoring the need for reforms to fully realize their benefits.
French Study Finds High Patient Satisfaction With Adalimumab Biosimilar Treatment for IBD
September 21st 2024An observational study assessing patient satisfaction with adalimumab for inflammatory bowel disease (IBD) reported a high level of satisfaction with all adalimumab product, including biosimilars.